Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This compound is a synthetic small molecule with the chemical formula C22H26N2O4 and a molecular weight of approximately 382.5 g/mol[1][7][8]. It is known by the code name GR166081 and DrugBank identifier DB06865[3][9]. The structure features an indan core substituted with hydroxy and hydroxyphenyl groups as well as a hexanoic acid side chain bearing a carbamimidoyl group. It has been categorized chemically as an amidine, amino fatty acid, aromatic homopolycyclic compound, carboxylic acid derivative, among others[2]. There is no evidence that this compound has reached clinical development or approval; it appears to be experimental with no marketed indications or established mechanism of action in humans[8][9].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 6-carbamimidoyl-2-[2-hydroxy-6-(4-hydroxy-phenyl)-indan-1-yl]-hexanoic acid.